Risk of proteinuria with atezolizumab plus bevacizumab versus lenvatinib in first-line systemic treatment for hepatocellular carcinoma.

被引：0
|
作者：
Yang, JIwon
Choi, Won-Mook
Kim, Hyung-Don
Choi, Jonggi
Yoo, Changhoon
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
机构：
[1] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Liver Ctr, Asan Med Ctr, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.558
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：558 / 558
页数：1
相关论文
共 50 条
  • [1] Higher Risk of Proteinuria with Atezolizumab plus Bevacizumab than Lenvatinib in First-Line Systemic Treatment for Hepatocellular Carcinoma
    Yang, Jiwon
    Choi, Won-Mook
    Kim, Hyung-Don
    Choi, Jonggi
    Yoo, Changhoon
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    LIVER CANCER, 2024,
  • [2] HIGHER RISK OF PROTEINURIA IN ATEZOLIZUMAB PLUS BEVACIZUMAB THAN LENVATINIB AS A FIRST-LINE SYSTEMIC TREATMENT IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Yang, Jiwon
    HEPATOLOGY, 2024, 80
  • [3] Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma
    Su, Chung-Wei
    Teng, Wei
    Lin, Po-Ting
    Jeng, Wen-Juei
    Chen, Kuei-An
    Hsieh, Yi-Chung
    Chen, Wei-Ting
    Ho, Ming-Mo
    Hsieh, Chia-Hsun
    Wang, Ching-Ting
    Chai, Pei-Mei
    Lin, Chen-Chun
    Lin, Chun-Yen
    Lin, Shi-Ming
    CANCER MEDICINE, 2023, 12 (06): : 7077 - 7089
  • [4] Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
    Park, Young-Gyu
    Kim, Hyung-Don
    Kim, Sejin
    Kim, Kyu-Pyo
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Yoo, Changhoon
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 467 - 467
  • [5] Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (08) : 1389 - 1397
  • [6] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Tovoli, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Niizeki, Takashi
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Stefanini, Bernardo
    Hiraoka, Atsushi
    Sho, Takuya
    Nishida, Naoshi
    Steup, Christoph
    Iavarone, Massimo
    Di Costanzo, Giovanni
    Marra, Fabio
    Tamburini, Emiliano
    Cabibbo, Giuseppe
    Foschi, Francesco Giuseppe
    Silletta, Marianna
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [7] Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
    Persano, M.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Cheon, J.
    Finkelmeier, F.
    Presa, J.
    Masi, G.
    Yoo, C.
    Lonardi, S.
    Piscaglia, F.
    Iavarone, M. A.
    Tamburini, E.
    Cabibbo, G.
    Silletta, M.
    Cascinu, S.
    Scartozzi, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2023, 34 : S603 - S604
  • [8] Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
    Chen, Yen-Hao
    Chen, Yen-Yang
    Wang, Jing-Houng
    Hung, Chao-Hung
    ANTICANCER RESEARCH, 2023, 43 (03) : 1377 - 1384
  • [9] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Giri, Suprabhat
    Angadi, Sumaswi
    Vaidya, Arun
    Singh, Ankita
    Roy, Akash
    Sundaram, Sridhar
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
  • [10] Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies
    Wang, Bi-Cheng
    Kuang, Bo-Hua
    Lin, Guo-He
    TARGETED ONCOLOGY, 2024, 19 (02) : 203 - 212
12345